August 24, 2020 – Biologics by McKesson was selected by Taiho Oncology, Inc. as a specialty pharmacy provider for INQOVI (decitabine and cedazuridine) tablets for the treatment of adults with intermediate and high-risk myelodysplastic syndromes (MDS) including chronic myelomonocytic leukemia (CMML), two blood malignancies.
INQOVI, approved by the U.S. Food and Drug Administration (FDA) on July 7, 2020, is a fixed-dose oral C-DEC (combination of decitabine and cedazuridine). The FDA granted this therapy orphan drug designation and approved INQOVI through its Priority Review process. By inhibiting cytidine deaminase in the gut and the liver, INQOVI enables the DNA hypomethylating agent, decitabine, to be taken orally for five days to reach systemic exposure levels that match those from five days’ worth of intravenous (IV) administration, the company says.
Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.
